Sanofi-Aventis to buy Genzyme for $20.1 bln cash

February 16, 2011 By GREG KELLER , AP Business Writer
In this May 28, 2008 file photo, Genzyme's Manufacturing Facility is seen in the Allston neighborhood of Boston. French drug maker Sanofi-Aventis SA has agreed to buy Genzyme Corp. in a sweetened all-cash deal that values the U.S. biotechnology company at $20.1 billion Wednesday, Feb. 16, 2011, ending months of corporate haggling.(AP Photo/Bizuayehu Tesfaye, file)

(AP) -- French drug maker Sanofi-Aventis SA has agreed to buy Genzyme Corp. in a sweetened all-cash $20.1 billion deal that ends months of corporate haggling and positions Sanofi at the forefront of the market in lucrative drugs for rare genetic disorders.

Sanofi-Aventis, the world's fourth-largest drug maker, overcame Genzyme's reluctance to a takeover by raising its previous offer and agreeing to make additional cash payments contingent on the success of several drugs.

The announcement comes after nearly nine months of back-and-forth between the two companies, with Sanofi-Aventis finally deciding Genzyme's portfolio of rare disease treatments was worth stumping up an extra five dollars a share to its original $69 per share offer.

The boards of both companies unanimously approved the deal, which is expected to close early in the second quarter, Sanofi-Aventis said in a statement.

Sanofi-Aventis chief Chris Viehbacher launched a hostile takeover bid for Cambridge, Massachusetts-based Genzyme last October, only to meet stiff resistance from Genzyme's founder and CEO Henri Termeer. The two sides have since softened their positions, with Genzyme opening its books to share confidential data with Sanofi-Aventis earlier this month, signaling a deal was near.

The agreement "will create a meaningful new growth platform for Sanofi-Aventis while expanding our footprint in biotechnology," Viehbacher said in a statement.

Sanofi-Aventis shares rose on the announcement, and in mid-afternoon trading Paris time were up 3.5 percent at euro51.56. In U.S. premarket trading, Genzyme stock rose $1.22 to $75.52.

Termeer will step down as chairman and CEO of Genzyme following completion of the deal, but will keep a consulting role as co-chairman with Viehbacher of an integration steering committee.

Genzyme would give Sanofi a new platform for growing its biotech business, let it expand into the growing - and lucrative - market for drugs for rare diseases, increase its U.S. presence and give it more experimental drugs in mid- and late-stage testing. Those include three for high cholesterol, a huge global market. And Genzyme has said it is close to resolving manufacturing problems that have limited sales of two key drugs for genetic disorders.

Genzyme's drugs for rare genetic disorders are in a hot niche for big pharmaceutical companies trying to diversify beyond blockbuster pills that get slammed by cheaper generic rivals after a decade or so. Genzyme won U.S. approval last May for a new drug for Pompe disease, an often fatal disorder in which limb and respiratory muscles steadily weaken. Its experimental drug for multiple sclerosis is getting an expedited U.S. review.

Genzyme's best-seller Cerezyme treats Gaucher disease, an enzyme disorder that can result in liver and neurological problems. Its second-best seller, Fabrazyme, treats an inherited disorder known as Fabry disease, which is caused by the buildup of a particular type of fat in the body's cells.

The deal gives Genzyme shareholders one "contingent value right" for each share owned. These CVRs give holders the right to cash payments based on Genzyme meeting certain goals, including raising production levels for Cerezyme and Fabrazyme, getting final FDA approval for multiple sclerosis treatment Lemtrada, and higher sales targets.

Genzyme says it expects three new product approvals by the end of 2013. Those are Lemtrada, a new Gaucher's disease treatment called eliglustat, and mipomersen, which is a treatment familial hypercholesterolemia, a genetic disorder that causes high cholesterol levels.

Genzyme also reported its fourth-quarter results Wednesday. The company said its profit climbed to $471.9 million, or $1.76 per share, from $23.2 million, or 9 cents per share a year ago. Excluding items like divestiture and acquisition costs and stock based compensation expenses, its profit rose to 82 cents per share from 29 cents per share. Its revenue climbed 23 percent, to $1.15 billion from $938.3 million.

Analysts expected a profit of 85 cents per share and $1.16 billion in revenue, according to FactSet. Analyst estimates generally exclude one-time items.

The company said sales of treatments for genetic disorders rose 45 percent to $505.6 million as it rebuilt its supplies of Cerezyme and Fabrazyme, and began selling its Pompe disease treatment Lumizyme in the U.S.

Explore further: Sanofi-Aventis says gets US approval for Genzyme bid


Related Stories

Sanofi-Aventis says gets US approval for Genzyme bid

October 20, 2010

French pharmaceutical giant Sanofi-Aventis said on Wednesday that US competition authorities had not raised any objections to its hostile bid for US biotechnology group and rare disease specialist Genzyme.

Genzyme board rejects Sanofi bid

August 30, 2010

The board of directors at US biotechnology firm Genzyme has unanimously rejected an 18.5-billion-dollar takeover offer from French pharmaceutical giant Sanofi-Aventis, Genzyme said Monday.

Sanofi extends bid for Genzyme

December 13, 2010

French pharmaceutical giant Sanofi-Aventis said Monday it had extended its bid for US biotechnology group Genzyme without improving an offer that attracted only a fraction of Genzyme shares.

Sanofi-Aventis launches Genzyme takeover battle

October 4, 2010

(AP) -- France's Sanofi-Aventis on Monday launched an $18.5 billion hostile takeover attempt for Genzyme Corp., escalating the battle after management of the U.S. biotech company twice rejected its offer.

Recommended for you

Microbial communities demonstrate high turnover

January 19, 2018

When Mark Twain famously said "If you don't like the weather in New England, just wait a few minutes," he probably didn't anticipate MIT researchers would apply his remark to their microbial research. But a new study does ...

Hot weather is bad news for bird sperm

January 19, 2018

A new study led by Macquarie University and spanning Sydney and Oslo has shown that exposure to extreme temperatures, such as those experienced during heatwave conditions, significantly reduces sperm quality in zebra finches, ...

More genes are active in high-performance maize

January 19, 2018

When two maize inbred lines are crossed with each other, an interesting effect occurs: The hybrid offspring have a significantly higher yield than either of the two parent plants. Scientists at the University of Bonn have ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.